http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Karale (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Pushpa A. Karale,Shashikant C. Dhawale,Mahesh A. Karale 경희대학교 융합한의과학연구소 2023 Oriental Pharmacy and Experimental Medicine Vol.23 No.4
Psoralea corylifolia L. has been used in traditional Chinese and Ayurvedic medicine systems for management of various diseases. The various phytochemical constituents work in orchestric manner to treat diverse illnesses. Current pharmacotherapies shown beneficiary role in treatment of dyslipidaemia but facing life threatening side effects. The usage of herbs increased worldwide and paves the way for development of pharmaceuticals for hyperlipidemia treatment. The main objective of present work was to investigate anti-hyperlipidemic activity and in-silico pancreatic lipase inhibitory potential of Psoralea corylifolia L. (PC) leaf extract. The existence of several phytoconstituents was confirmed by the chromatographic research and mainly includes the flavonoids and furanocoumarins. All studied phytoconstituents were found to have superior binding affinity than standard orlistat (− 7.1 kcal/mol), with docking score ranges from − 10.6 to − 7.3 kcal/mol. At 200 mg/ kg/day the ethanolic leaf extract demonstrated highest lipid lowering action. Ethanolic leaf extract of Psoralea corylifolia revealed evidential antihyperlipidemic potential in a concentration dependent manner (P < 0.01). The serum lipid profile (LDL, VLDL, TG, TC) dropped firmly and HDL elevated in hyperlipidemic rats treated with plant extract compared with the hyperlipidemic group rats (P < 0.01). The hepatic TC and TG abruptly increased in hyperlipidemic rats and significantly reduced in hyperlipidemic rats administered with EPC compared with the control group (P < 0.01). The hyperlipidemic rats treated with atorvastatin and PC at different doses shown evidentiary increase in secretion of TC and TG compared with the hyperlipidemic group rats. The study results proposed that EPC leaf extract demonstrated noteworthy antihyperlipidemic action. The findings of docking study recommend utilization of the best ligands experimentally to develop novel anti-obesity agents. Psoralea corylifolia L. has been used in traditional Chinese and Ayurvedic medicine systems for management of various diseases. The various phytochemical constituents work in orchestric manner to treat diverse illnesses. Current pharmacotherapies shown beneficiary role in treatment of dyslipidaemia but facing life threatening side effects. The usage of herbs increased worldwide and paves the way for development of pharmaceuticals for hyperlipidemia treatment. The main objective of present work was to investigate anti-hyperlipidemic activity and in-silico pancreatic lipase inhibitory potential of Psoralea corylifolia L. (PC) leaf extract. The existence of several phytoconstituents was confirmed by the chromatographic research and mainly includes the flavonoids and furanocoumarins. All studied phytoconstituents were found to have superior binding affinity than standard orlistat (− 7.1 kcal/mol), with docking score ranges from − 10.6 to − 7.3 kcal/mol. At 200 mg/ kg/day the ethanolic leaf extract demonstrated highest lipid lowering action. Ethanolic leaf extract of Psoralea corylifolia revealed evidential antihyperlipidemic potential in a concentration dependent manner (P < 0.01). The serum lipid profile (LDL, VLDL, TG, TC) dropped firmly and HDL elevated in hyperlipidemic rats treated with plant extract compared with the hyperlipidemic group rats (P < 0.01). The hepatic TC and TG abruptly increased in hyperlipidemic rats and significantly reduced in hyperlipidemic rats administered with EPC compared with the control group (P < 0.01). The hyperlipidemic rats treated with atorvastatin and PC at different doses shown evidentiary increase in secretion of TC and TG compared with the hyperlipidemic group rats. The study results proposed that EPC leaf extract demonstrated noteworthy antihyperlipidemic action. The findings of docking study recommend utilization of the best ligands experimentally to develop novel anti-obesity agents. Keywords Psoralea
-
Shelke, Sharad,Salunkhe, Nilesh,Sangale, Sandeep,Bhalerao, Swapnil,Naik, Nilesh,Mhaske, Ganesh,Jadhav, Ranjana,Karale, Bhausaheb Korean Chemical Society 2010 대한화학회지 Vol.54 No.1
일련의 불소화된 티아디아졸 3, 트리아졸 4, 그리고 옥사디아졸 5이 (2-(6-Methyl-2-P-tolyl-lH-imidazo[1,2-a]pyridin-3-yl)핵종을 가지고 있는 티오세미카르바지드로 부터 합성되어진다. 초음파조사 방법 뿐만 아니라 일반적인 방법에 의해 반응이 진행되었다. 모든 생성물들은 IR, 1H NMR, MS로 구조가 결정되었고, 이들 화합물의 항균활성을 스크닝하였다. The synthesis of a series of fluorinated thiadiazoles 3, triazoles 4 and oxadiazoles 5 are synthesized from thiosemicarbazides 2 containing (2-(6-methyl-2-p-tolyl-lH-imidazo[1,2-a]pyridin-3-yl nucleus. These reactions were carried out by conventional method as well as ultra sound irradiation method. All products have been characterized by IR, 1H NMR, MS study and screened for their antimicrobial activity.
-
Mustafa Erkan Sarı,Mehmet Mutlu Meydanlı,Osman Türkmen,Günsü Kimyon Cömert,Ahmet Taner Turan,Alper Karalök,Hanifi Şahin,Ali Haberal,Eda Kocaman,Özgür Akbayır,Baki Erdem,Ceyhun Numanoğlu,Kemal Güngördü 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.4
Objective: To assess the prognosis of surgically-staged non-invasive uterine clear cell carcinoma (UCCC), and to determine the role of adjuvant therapy. Methods: A multicenter, retrospective department database review was performed to identify patients with UCCC who underwent surgical treatment between 1997 and 2016 at 8 Gynecologic Oncology Centers. Demographic, clinicopathological, and survival data were collected. Results: A total of 232 women with UCCC were identified. Of these, 53 (22.8%) had surgically-staged non-invasive UCCC. Twelve patients (22.6%) were upstaged at surgical assessment, including a 5.6% rate of lymphatic dissemination (3/53). Of those, 1 had stage IIIA, 1 had stage IIIC1, 1 had stage IIIC2, and 9 had stage IVB disease. Of the 9 women with stage IVB disease, 5 had isolated omental involvement indicating omentum as the most common metastatic site. UCCC limited only to the endometrium with no extra-uterine disease was confirmed in 41 women (73.3%) after surgical staging. Of those, 13 women (32%) were observed without adjuvant treatment whereas 28 patients (68%) underwent adjuvant therapy. The 5-year disease-free survival rates for patients with and without adjuvant treatment were 100.0% vs. 74.1%, respectively (p=0.060). Conclusion: Extra-uterine disease may occur in the absence of myometrial invasion (MMI), therefore comprehensive surgical staging including omentectomy should be the standard of care for women with UCCC regardless of the depth of MMI. Larger cohorts are needed in order to clarify the necessity of adjuvant treatment for women with UCCC truly confined to the endometrium.
DBpia
ScienceON연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
